effect overlay
activetrials
Dementia
Dementia
3D

Deferiprone to Delay Dementia (The 3D Study): a clinical proof of cencept study
 

HREC: 2017.172
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Lauren Martell
Funding: Commercial
Dementia
Dementia
Anavex 003

A Phase IIa Study of ANAVEX2-73 Adaptive Trial Design with repeated doses, Maximum Tolerated Dose Finding, Pharmacodynamic Investigation and Bioavailability Evaluation in Patients with Mild to Moderate Alzheimer’s Disease With a 52 week Open Label Follow-Up period 
 

HREC: 2016.097
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Lauren Martell
Funding: Commercial